Financial Performance Summary - The company reported total revenue of 235 million yuan for the first half of 2025, a decrease of 2.93% year-on-year [1] - The net profit attributable to shareholders was 18.55 million yuan, down 72.92% compared to the previous year [1] - The gross profit margin was 21.9%, reflecting a significant decline of 39.16% year-on-year [1] - The net profit margin decreased to 7.9%, down 72.1% from the previous year [1] - The total of selling, administrative, and financial expenses amounted to 26.98 million yuan, accounting for 11.49% of revenue, an increase of 334.54% [1] Key Financial Metrics - Revenue for 2024 was 242 million yuan, compared to 235 million yuan in 2025 [1] - The net profit for 2024 was 68.50 million yuan, while it dropped to 18.55 million yuan in 2025 [1] - The cash and cash equivalents decreased by 47.18% to 540 million yuan [1] - The company's earnings per share fell to 0.06 yuan, a decrease of 75% year-on-year [1] Expense Analysis - Selling expenses increased by 13.2% due to heightened sales efforts [2] - Financial expenses surged by 85.51% primarily due to reduced interest income [3] - Research and development expenses decreased by 17.72% as fewer projects were initiated compared to the previous period [4] Cash Flow Insights - Net cash flow from operating activities decreased by 73.71% due to reduced interest income [4] - Net cash flow from investing activities increased by 109.22% as fewer large certificates of deposit were purchased [4] - Net cash flow from financing activities rose by 47.33% due to a reduction in dividend distribution compared to the previous year [4] Company Strategy and Future Plans - The company currently has no plans for share buybacks, but will disclose any future plans in accordance with regulations [5]
亨迪药业（301211）2025年中报简析：净利润减72.92%，三费占比上…